A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Abstract Objective APPEASE is a phase I study to assess the safety, dosing, and efficacy of rivoceranib (a selective, small-molecule inhibitor of VEGFR2) in combination with pembrolizumab. We aimed to treat patients with metastatic malignancies who have progressed through at least first-line therapy...

Full description

Bibliographic Details
Main Authors: Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati Gupta
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Research Notes
Subjects:
APPEASE
Apatinib
Rivoceranib
Pembrolizumab
Immunotherapy
VEGF inhibition
Online Access:https://doi.org/10.1186/s13104-023-06283-5

Internet

https://doi.org/10.1186/s13104-023-06283-5

Similar Items